BPGAM
MRTX

BTG Pactual Global Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BTG Pactual Global Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,000
Closed -$516K – 110
2015
Q3 		$516K Buy
+15,000
New +$453K 0.04% 141

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BTG Pactual Global Asset Management's MRTX Position: Q4 2015 in Review

BTG Pactual Global Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2015, closing a stake of 15,000 shares — an estimated $516K sold.

BTG Pactual Global Asset Management first reported a position in MRTX in Q3 2015 and held it in 1 quarter. The position peaked at $516K in Q3 2015. 80 funds tracked by Wall St. Rank hold MRTX as of Q4 2015.

  • BTG Pactual Global Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 15,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $516K.
  • BTG Pactual Global Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • BTG Pactual Global Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $516K in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2015.

Based on BTG Pactual Global Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.